Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Denmark
Aarhus Universitetshospital - Skejby, Aarhus, Denmark Copenhagen Rigshospitalet, Copenhagen, Denmark Germany
Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Dresden Klinikum der Universität München Großhadern, Munich, Munich Charite Campus Virchow-Klinikum, Berlin, State of Berlin